中国平安(02318.HK)人工智能医疗系统系计用量3,300万次
中国平安(02318.HK)公布,旗下平安智慧医疗已研发出一套可准确识别视网膜疾病的人工智能自动化系统,并转介急症病人到专科医生求诊,填补医疗资源缺口。
公司表示,其研发的人工智能诊断和治疗辅助工具「AskBob医生」於中国筛查了超过13,000名患者,其中近4,000名患者被诊断患有不同程度的眼疾,并有1,300名患者需要立即接受治疗以防止视力受损。
截至2020年7月,平安智慧医疗网络覆盖中国90个城市及17,000多间医疗机构。AskBob医生自2019年6月推出以来,已为43万名医生提供智能辅助诊疗及智能随访患教等服务,累计调用量达3,300万次。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.